Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
In Case You Missed It Nov. 9: Goldman, GoPro, GTT and the GOP

In Case You Missed It Nov. 9: Goldman, GoPro, GTT and the GOP

Impax is Slowly Stealing Market Share from Mylan; Goldman Names New Partners; Twinkie Maker Hostess Brands Preps for Its Next Chapter; and more from The Street.

Rosen Law Firm Continues To Investigate Securities Claims Against Impax Laboratories Inc. To Recover Investor Losses - IPXL

Rosen Law Firm Continues To Investigate Securities Claims Against Impax Laboratories Inc. To Recover Investor Losses - IPXL

Rosen Law Firm, a global investor rights law firm, announces that it continues to investigate potential securities claims on behalf of shareholders of Impax Laboratories Inc.

Glancy Prongay & Murray Commences Investigation On Behalf Of Impax Laboratories Inc. Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices

Glancy Prongay & Murray Commences Investigation On Behalf Of Impax Laboratories Inc. Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Impax Laboratories Inc.

Impax is Slowly Stealing Market Share from Mylan, but Manufacturing Could Get in the Way

Impax is Slowly Stealing Market Share from Mylan, but Manufacturing Could Get in the Way

Impax makes a generic version of Adrenaclick, a competitor to Mylan's EpiPen.

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Here are Monday's top research calls, including upgrades for Biogen and Time Warner, and downgrades for GoPro and L Brands.

After Big Drop in Generics, Ride the Rebound

After Big Drop in Generics, Ride the Rebound

Investors have a buying opportunity because the damage by any criminal charges is far less than what is likely to be inflicted by the feds.

Generics Hit by Report on Pending DOJ Price Fixing Charges

Generics Hit by Report on Pending DOJ Price Fixing Charges

The DOJ's investigation has been under way for at least two years and a number of companies have reported receiving subpoenas related to the investigation.

Health Sector Down As Report of Industry Price Collusion Surfaces

Health Sector Down As Report of Industry Price Collusion Surfaces

The healthcare sector was dragged down by reports of price collusion and worse-than-expected third-quarter profits.

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

India drugmaker Intas will pay about $770 million for the UK and Ireland generics assets.

Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

'Mad Money' Lightning Round: I Am Committed to Opko Health

'Mad Money' Lightning Round: I Am Committed to Opko Health

Cramer says SolarCity is too hard for him and he's losing patience with Cigna.

Jim Cramer's 'Mad Money' Recap: These Are the Sectors to Buy Now

Jim Cramer's 'Mad Money' Recap: These Are the Sectors to Buy Now

With interest rate hikes this year a distinct possibility, the big money managers are springing into action, Cramer says. Here's what to buy.

Impax Laboratories Stock Sees Short Interest Decline 42%

Impax Laboratories Stock Sees Short Interest Decline 42%

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 2,335,857 share decrease in total short interest for Impax Laboratories Inc , to 3,238,440, a decrease of 41.90% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax (IPXL) Stock Plummets on Weak Q2 Results, Guidance

Impax (IPXL) Stock Plummets on Weak Q2 Results, Guidance

Impax (IPXL) reported lower-than-anticipated earnings and revenue for the 2016 second quarter and a downbeat forecast before Tuesday's market open.

Changing Landscape for Generic-Drug Makers Creates Opportunities

Changing Landscape for Generic-Drug Makers Creates Opportunities

The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.

Short Interest Expands By 12.8% For IPXL

Short Interest Expands By 12.8% For IPXL

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 709,063 share increase in total short interest for Impax Laboratories Inc , to 6,260,150, an increase of 12.77% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Teva Inches Closer to Completion of Allergan Generics Deal

Teva Inches Closer to Completion of Allergan Generics Deal

Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.

Impax Laboratories (IPXL) Marked As A Dead Cat Bounce Stock

Impax Laboratories (IPXL) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a "dead cat bounce" (down big yesterday but up big today) candidate

What Exactly Did Allergan and Teva Sell to Impax?

What Exactly Did Allergan and Teva Sell to Impax?

The deal helps the Israeli drug giant comply with required antitrust divestitures connected to completion of its $40.5 billion acquisition of the generics business of Allergan.

Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal

Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal

Impax Laboratories (IPXL) stock is plunging after the company agreed to buy a portfolio of generic drugs from Teva Pharmaceuticals (TEVA) and Allergan (AGN) for $586 million.

Impax Laboratories (IPXL) Highlighted As Weak On High Volume

Impax Laboratories (IPXL) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a weak on high relative volume candidate

4 More Good 'Chicken Shorts'

These overpriced stocks lend themselves to puts or put spreads.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CAG, CCBG, CREE, ESRT, MLNX, MPX, PDCO, TMUS, VSAT, WMT Downgrades: BKU, FFIN, INSY, IPXL, LM, MGLN, MRC, THC Initiations: ONDK, VLRS Read on to get TheStreet Quant Ratings' detailed report:

Impax Laboratories (IPXL) Stock Drops Despite Earnings Beat

Impax Laboratories (IPXL) Stock Drops Despite Earnings Beat

Impax Laboratories (IPXL) stock is declining on Monday after posting its 2015 fourth quarter results before today’s opening bell.

Impax Laboratories (IPXL) Strong on High Relative Volume Today

Impax Laboratories (IPXL) Strong on High Relative Volume Today

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a strong on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AZN, HZO, IPXL, SCAI, YY Downgrades: ADUS, CS, CSTE, EEI, FDUS, FNV, MDU, MSON, PEGI, TRC Initiations: HYH Read on to get TheStreet Quant Ratings' detailed report:

Perilous Reversal Watch: Impax Laboratories (IPXL)

Perilous Reversal Watch: Impax Laboratories (IPXL)

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a "perilous reversal" (up big yesterday but down big today) candidate

Impax Laboratories (IPXL) Flagged As Strong On High Volume

Impax Laboratories (IPXL) Flagged As Strong On High Volume

Trade-Ideas LLC identified Impax Laboratories (IPXL) as a strong on high relative volume candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: None Downgrades: BWINB, CBS, CGI, DCUA, DCUB, IPXL, KING, KTWO, THR Initiations: LOCO Read on to get TheStreet Quant Ratings' detailed report: